Ken Griffin Arcus Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $25,211 - $34,306	1,700 Added 9.19%	20,200 $381,000
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $5,372 - $7,852	-400 Reduced 2.12%	18,500 $353,000
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $280,158 - $374,286	-15,900 Reduced 45.69%	18,900 $339,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $203,640 - $264,360	12,000 Added 52.63%	34,800 $706,000
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $102,144 - $148,160	6,400 Added 39.02%	22,800 $415,000

Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $323,080 - $585,644	16,400 New	16,400 $339,000

186

49.2M

204K

149K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.1B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.